Transmitted HIV type 1 drug resistance and non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy

AIDS Research and Human Retroviruses

Volumn 26, Issue 1, 2010, Pages 41-49

  Riva, Chiara ^a   Lai, Alessia ^a   Caramma, Ilaria ^a   Corvasce, Stefano ^a   Violin, Michela ^a   Dehò, Lorenzo ^a   Prati, Francesca ^b   Rossi, Cristina ^c   Colombo, Maria Chiara ^d   Capetti, Amedeo ^a   Franzetti, Marco ^a   Rossini, Valeria ^a   Tambussi, Giuseppe ^e   Ciccozzi, Massimo ^f   Suligoi, Barbara ^f   Mussini, Cristina ^b   Rezza, Giovanni ^f   Balotta, Claudia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c SAN CAMILLO HOSPITAL   (Italy)

^d SANT ANNA HOSPITAL   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f Italian Institute of Health   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; ITALY; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRIORITY JOURNAL; SEROCONVERSION; VIRUS TRANSMISSION; VIRUS TYPING;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 76449092247     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0057     Document Type: Article

References (38)

1. Hirsch M, Günthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008;47:266-285.
2. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
3. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929.
4. Musicco M, Lazzarin A, Nicolosi A, et al.: Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexuals transmission. Arch Intern Med 1994;154:1971-1976.
5. Yerly S, Vora S, Rizzardi P, et al.: Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. AIDS 2001;15:2287-2292.
6. De Mendoza C, Del Romero J, Rodriguez C, Corral A, and Soriano V: Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS 2002;16:1830-1832.
7. Violin M, Velleca R, Cozzi-Lepri A, et al.: Prevalence of HIV- 1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr 2004;36:761-764.
8. Descamps D, Flandre P, Calvez, et al.: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction- maintenance therapy. J Am Med Assoc 2000;283:205-211.
9. Back D, Gatti G, Fletcher C, et al.: Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002;16:S5-37.
10. Richman DD, Morton SC, Wrin, et al.: The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-1401.
11. Tamalet C, Fantini J, Tourres C, and Yahi N: Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003;17:2383-2388.
12. Scott P, Arnold E, Evans B, et al.: Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 2004;53:469-473.
13. Caramma I, Violin M, Vellica R, et al.: Study of antiretroviral resistance in treated patients with virological failure (START study): Temporal trends of class resistance evaluated in patients failing last HAART. XVI International HIV Drug Resistance Workshop, 12-16 June 2007, Barbados, West Indies. Abstract 53.
14. Di Giambenedetto S, Bracciale L, Colafigli M, et al.: Declining prevalence of HIV-1 drug resistance in treatment-failing patients: A clinical cohort study. Antivir Ther 2007;12:835-839.
15. Pillay D: Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004;9:695-702.
16. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
17. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223.
18. Barbour JD, Hecht FM, Wrin T, et al.: Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18:1683-1689.
19. Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
20. Shet A, Berry L, Mohri H, et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41:439-446.
21. Wensing AM, Van De Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192:958-966.
22. Pillay D, Bhaskaran K, Jurriaans S, et al.: The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006;20: 21-28.
23. The SPREAD programme: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008;22:625-635.
24. UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study; UK Register of HIV Seroconverters: Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007;21:1035-1039.
25. Not Ist Super Sanità 2007;20(Suppl 1):1-24 (www.iss.it).
26. Balotta C, Facchi G, Violin M, et al.: Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immun Defic Syndr 2001;27:499-505.
27. Rusconi S, De Pasquale MP, Milazzo L, et al.: Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing openlabel trial. Antivir Ther 1997;2:39-46.
28. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Spring2008. Top HIV Med 2008;16:62-68.
29. Violin M, Cozzi-Lepri A, Velleca R, et al.: Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004;18:227-235.
30. Blower SM, Aschenbach AN, Gershengorn HB, and Kahn JO: Predicting the unpredictable: transmission of drugresistant. HIV. Nat Med 2001;7:1016-1020.
31. Turner D, Brenner B, Routy JP, Moisi D, et al.: Diminished representation of HIV-1 variants containing select drug resistance- conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1627-1631.
32. Corvasce S, Violin M, Romano L, et al.: Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther 2006;11:329-334.
33. Yerly S, Von Wyl V, Ledergerber B, et al.: Transmission of HIV-1 drug resistance in Switzerland: A 10-year molecular epidemiology survey. AIDS 2007;21:2223-2229.
34. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, and Heneine W: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drugnaive persons. Proc Natl Acad Sci USA 2001;98:13907-13912.
35. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
36. Ciccozzi M, Montieri S, Salemi M, et al.: An outbreak of HIV- 1 subtype G among Italian injecting drug users. AIDS 2007;21(9):1213-1225.
37. Ghosn J, Pellegrin I, Goujard C, et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20:159-170.
38. Simen BB, Hullsiek KH, Novak RM, et al.: Prevalence of low abundant drug-resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral (ARV)-naïve patients and the impact on virological outcomes. XVI International HIV Drug Resistance Workshop, 12-16 June 2007, Barbados, West Indies. Abstract 134.